-
08:58:39 PM

TAK Stock News

11/22/22 3:57 PM
NYSE : TAK
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
In the U.S., TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age. Dengue is a mosquito-borne virus endemic in more than 125 countries, including the U.S. territories of Puerto Rico, the U.S. Virgin Islands and American Samoa. 1,2 Incidence of dengue has increased globally...
RHEA-AI
neutral
11/17/22 8:00 AM
NYSE : TAK
clinical trial
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
Takeda today announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated with ICLUSIG ® plus reduced-intensity chemotherapy achieved higher rates of minimal residual...
RHEA-AI
neutral
11/11/22 2:00 AM
NYSE : TAK
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
Takeda today announced that the European Commission has granted Marketing Authorization for LIVTENCITY TM for the treatment of cytomegalovirus infection and/or disease that are refractory to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet, in adult patients who have undergone a...
RHEA-AI
neutral
10/14/22 7:30 AM
NYSE : TAK
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
TAK-003 Recommended for the Prevention of Dengue Disease Caused by Any Dengue Virus Serotype in Individuals Four Years of Age and Older in the EU and in Dengue-Endemic Countries Participating in the EU-M4all Procedure Positive Opinion for TAK-003 Based on 4.5 Years of Safety and Efficacy Data from Pivotal Phase 3 Trial of Over 20,000 Children and...
RHEA-AI
neutral
10/05/22 8:09 AM
NYSE : TAK
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
Takeda today announced that the U.S. Food& Drug Administration has accepted a supplemental Biologics License Application for the potential expanded use of TAKHZYRO ® for prophylaxis to prevent attacks of hereditary angioedema in pediatric patients 2 to 1-3 The FDA has granted priority review of the application and indicated a decision is expected in the...
RHEA-AI
neutral
09/19/22 8:00 AM
NYSE : TAK
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
Takeda and Enel North America today announced the signing of a long-term virtual power purchase agreement for the electricity delivered to the power grid from a 79 megawatt portion of Enel’ s Seven Cowboy wind project in the state of Oklahoma in the U.S. The agreement, advised by Edison Energy LLC, advances progress towards achieving...
RHEA-AI
positive
09/16/22 8:00 AM
NYSE : TAK
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
Takeda today announced the European Medicines Agency’ s Committee for Medicinal Products for Human Use has recommended the approval of maribavir for the treatment of cytomegalovirus infection and/or disease that are refractory to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in...
RHEA-AI
neutral